Search results for "Highlights"
SGLT-2 inhibitors associated with reduced heart failure events versus metformin
A retrospective study of patients who took sodium-glucose cotransporter-2 (SGLT-2) inhibitors or metformin as first-line therapy for type 2 diabetes found similar risk for myocardial infarction and stroke with the two drug classes but a difference in hospitalizations for heart failure.
https://diabetes.acponline.org/archives/2022/06/10/2.htm
10 Jun 2022
Cystatin C levels associated with risk of sight-threatening diabetic retinopathy
The biomarker may be useful for predicting this condition, especially in areas that don't have access to retinal imaging, according to an analysis of ophthalmology patients in the United Kingdom and India.
https://diabetes.acponline.org/archives/2022/05/13/3.htm
13 May 2022
Manufacturer's trials find positive results for combo drug for type 2 diabetes
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
https://diabetes.acponline.org/archives/2021/07/09/3.htm
9 Jul 2021
Whole, plant-based diet most effective for type 2 diabetes remission, ACLM says
Diet as a primary intervention can achieve remission for many with type 2 diabetes and should focus on plant-based foods with minimal consumption of meat and other animal products, according to a statement from the American College of Lifestyle Medicine (ACLM).
https://diabetes.acponline.org/archives/2022/06/10/3.htm
10 Jun 2022
Glucose-lowering treatment after type 2 diabetes diagnosis differed by race/ethnicity
Among 77,199 patients in a U.S. health system with a new diagnosis of diabetes from 2005 to 2016, 47% started a diabetes medication within 12 months. Prevalence differed by race and ethnicity, although the difference was mitigated by variation in HbA1c levels.
https://diabetes.acponline.org/archives/2022/08/12/3.htm
12 Aug 2022
GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
https://diabetes.acponline.org/archives/2022/04/08/2.htm
8 Apr 2022
Spotlight on efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists
One recent study compared sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to each other, a meta-analysis tried to quantify their benefits compared to placebo, and a third study looked at their effects relative to insulin.
https://diabetes.acponline.org/archives/2022/05/13/5.htm
13 May 2022
Statins compared for non-HDL cholesterol levels in patients with diabetes
Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2022/04/08/1.htm
8 Apr 2022
Unrecognized risk factors for severe hypoglycemia outlined in insulin-treated type 2 diabetes
An industry-funded case-control study of data from a U.S. administrative claims database found that pregnancy, alcohol misuse, short or rapid-acting insulin, and smoking, among other conditions and medications, were independently associated with increased risk.
https://diabetes.acponline.org/archives/2022/04/08/3.htm
8 Apr 2022
SGLT-2 inhibitors reduce cardiac events, mortality compared to DPP-4 inhibitors
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were associated with lower risk of cardiovascular events compared to dipeptidyl peptidase-4 (DPP-4) inhibitors but higher risk of genital infections and diabetic ketoacidosis, a retrospective study found.
https://diabetes.acponline.org/archives/2023/02/10/1.htm
10 Feb 2023